陈国强特聘讲座教授

--------------------------------------------------------------------------------
陈国强教授，男，研究员。1988年和1996年分获上海第二医科大学硕士和内科血液学博士学位，并先后在法国和美国从事高访。现任国家重点基础研究计划首席科学家，上海第二医科大学病理生理学教研室主任，中国科学院上海生命科学研究院/上海第二医科大学健康科学中心肿瘤功能基因组学研究室主任，上海第二医科大学附属瑞金医院上海血液学研究所副所长。《癌症》杂志副主编、《中华医学杂志》和《肿瘤防治杂志》等编委。


研究方向
--------------------------------------------------------------------------------
陈国强教授领导的课题组强调从事科学假说和兴趣驱动的原创性研究，强调学科前沿和国家需求，主要开展治疗肿瘤的药物靶基因的基础性探索性工作，具体研究内容主要包括：识别白血病相关的AML1、ETO和AML1-ETO的相互作用蛋白并探讨它们在AML1-ETO信号中的作用；M2b白血病蛋白的AML1-ETO调控基因，并研究其功能；白血病蛋白质组学研究；应用蛋白质芯片技术分析肿瘤血清标志物和肿瘤细胞分化和凋亡机制研究。他要求他的研究生在答辩之前，学位论文必须由影响因子3以上的国际权威杂志所接受发表。

获奖成果
--------------------------------------------------------------------------------
多年来，一直致力于白血病分子发病学和治疗学机制研究，尤其是他所从事的三氧化二砷治疗急性早幼粒细胞性白血病（APL）的基础和临床研究工作在国际血液学界开拓了一种全新的研究领域。最近，他领导的课题组在低氧诱导因子（HIF-1）和磷脂爬行酶（PLSCR1）介导白血病分化中的作用及其表达调控机制研究方面取得系列原创发现，在利用蛋白质组学技术研究白血病相关蛋白的功能方面也取得重要进展。近几年来，他在国际权威刊物《BLOOD》、《JNCI》、《PNAS》、《LEUKEMIA》以及国内核心期刊共发表了70余篇学术论文。自97年以来，在全国单篇论文引用数统计排名中始终处于前八位，共达1400余次。他先后获得杰出青年科学基金、国家自然科学基金、国家973计划、中科院百人计划、国家科技部国际合作重大项目、霍英东高校青年教师基金、卫生部优秀青年科技人才专项基金、上海青年启明星计划和上海科技发展重大项目的资助，并获得国家自然科学二等奖、上海市科技进步一等奖、杜邦科技创新奖、中国青年科技奖等学术奖励和新世纪首批百千万人才工程国家级人选、上海“十大杰出青年”、上海科技英才、上海市劳动模范、上海市优秀学科带头人、上海优秀青年教师、市卫生系统杰出青年人才“银蛇奖”等荣誉称号，并享受国务院特殊津贴。

代表性论著
--------------------------------------------------------------------------------
1.Ke-WenZhao,XiLi,QianZhao,YingHuang,Zhen-GangPeng,Wu-ZhongShen,JiZhao,QuanshengZhou,ZhuChen,PeterJ.Sims,ThereseWiedmer,andChenGQ.ProteinKinaseCMediatesRetinoicAcidandPhorbolMyristateAcetate-inducedPhospholipidScramblase1GeneExpression:ItsRoleinLeukemicCellDifferentiation.BLOOD，2004,in　press.
2.YinT,WuYL,SunHP,SunGL,DuYZ,WangKK,ZhangJ,ChenGQ,ChenSJ,ChenZ.CombinedeffectsofAs4S4andimatinibonchronicmyeloidleukemiacellsandBCR-ABLoncoprotein.Blood.2004,inpress
3.YiJIANG,Wu-ZhongSHEN,Zhi-HongXUE,HuaYAN,Zhen-GangPENG,Jian-HuaTONG,ZhuCHEN,YingHUANG,MichealLÜBBERTandChenGQ.DesferrioxamineInducesLeukemicCellDifferentiationByHypoxiaInducibleFactor-1aAndCCAAT/enhancer-bindingProtein--DependentMechanisms.Leukemia,inrevision
4.YunYu,ShengChen,Li-ShunWang,Wen-LiChen,Wei-JianGuo,HuaYan,Wei-HuaZhang,Cheng-HongPeng,Sheng-DaoZhang,Hong-WeiLi,ChenGQ.PredictionofSerumBiomarkersForPancreaticCancerBySurfaceEnhancedLaserDesorption/ionization-basedDecisionTreeClassification.ONCOLOGY,2004,inpress
5.HuangY,DuKM,XueZH,YanH,LiD,LiuW,ChenZ,ZhaoQ,TongJH,ZhuYS,ChenGQ.Cobaltchlorideandlowoxygentensiontriggerdifferentiationofacutemyeloidleukemiccells:possiblemediationofhypoxia-induciblefactor-1alpha.Leukemia.2003Nov;17(11):2065-73.
6.CaiX,YuY,HuangY,ZhangL,JiaPM,ZhaoQ,ChenZ,TongJH,DaiW,ChenGQ.Arsenictrioxide-inducedmitoticarrestandapoptosisinacutepromyelocyticleukemiacells.Leukemia.2003Jul;17(7):1333-7.
7.ChenGQ,ZhouL,StybloM,WaltonF,JingY,WeinbergR,ChenZ,WaxmanS.Methylatedmetabolitesofarsenictrioxidearemorepotentthanarsenictrioxideasapoptoticbutnotdifferentiationinducersinleukemiaandlymphomacells.CancerRes.2003Apr15;63(8):1853-9.
8.ZhaoQ,TaoJ,ZhuQ,JiaPM,DouAX,LiX,ChengF,WaxmanS,ChenGQ,ChenSJ,LanotteM,ChenZ,TongJH.RapidinductionofcAMP/PKApathwayduringretinoicacid-inducedacutepromyelocyticleukemiacelldifferentiation.Leukemia.2003；18（20）：285
9.GuBW,XiongH,ZhouY,ChenB,WangL,DongS,YuZY,LuLF,ZhongM,YinHF,ZhuGF,HuangW,RenSX,GallagherRE,WaxmanS,ChenGQ,WangZG,ChenZ,FuG,ChenSJ.Variant-typePML-RAR(alpha)fusiontranscriptinacutepromyelocyticleukemia:useofacrypticcodingsequencefromintron2oftheRAR(alpha)geneandidentificationofanewclinicalsubtyperesistanttoretinoicacidtherapy.ProcNatlAcadSciUSA.2002May28;99(11):7640-5.
10.JingYK，WangL，Guo-QiangChen,WaxmanS.Combinedeffectsofall-transretinoicacidandarsenictrioxideinAPLcellsinvitroandinvivo.Blood,2001,97(1):264-9
11.ChenZ,ChenGQ,ShenZX,SunGL,TongJH,WangZY,ChenSJ.Expandingtheuseofarsenictrioxide:leukemiasandbeyond.SeminHematol2002Apr;39(2Suppl1):22-6
12.ZhaoWL,ChenSJ,ShenY,XuL,CaiX,ChenGQ,ShenZX,ChenZ,WangZY.Treatmentofacutepromyelocyticleukemiawitharsenictrioxide:clinicalandbasicstudies.LeukLymphoma2001Nov-Dec;42(6):1265-73
13.ZhangTD,ChenGQ,WangZG,WangZY,ChenSJ,ChenZ.Arsenictrioxide,atherapeuticagentforAPL.Oncogene2001Oct29;20(49):7146-53
14.ChenZ,ChenGQ,ShenZX,ChenSJ,WangZY.Treatmentofacutepromyelocyticleukemiawitharseniccompounds:invitroandinvivostudies.SeminHematol2001Jan;38(1):26-36
15.XunCai,Yu-LeiShen,QiZhu,Pei-MinJia,YunYu,LiZhou,YingHuang,Ji-WangZhang,Shu-MinXiong,Sai-JuanChen,Zhen-YiWang,ZhuChen,andChenGQ.As2O3–inducedAPLcellApoptosisandDifferentiationAreAssociatedRespectivelywithMitochondrialTransmembranePotentialCollapse/CaspaseActivationandRASignaling.Leukemia.2000;14:262
16.Xin-HuaZhu,Yu-LeiShen,Yong-kuiJing,XunCai,Pei-MingJia,YingHuang,WeiTang,Gui-YingShi,Yue-PingSun,JieDai,Zhen-YiWang,Sai-JuanChen,Ting-DongZhang,SamuelWaxman,ZhuChen,ChenGQ.ApoptosisandGrowthInhibitioninMalignantLymphocytesaftertreatmentwithArsenicTrioxideatClinicallyachievableConcentrations.JNatlCancerInst.1999;91(9):772-8
17.G-XCheng,XHZhu,X-QMen,LWang,QHHuang,X-LJin,SMXiong,JZhu,WMGuo,JQChen,SFXu,ESo,LCChan,SWaxman,AZelent,Guo-QiangChen,SDong,JXLiu,S-JChen.DistinctleukemiaPhenotypesinTrabsgenicMiceandDifferentCorepressorInteractionsGeneratedbyPromyelocyticLeukemiaVariantFusionGenesPLZF-RARandNPM-RARa.ProcNatlAcadSciUSA.1999;96:6318-6323
18.NiuC,YanH,LiuJX,YuT,SunHP,LiXS,WuW,ZhangFQ,ChenY,ZhouL,LiJM,ZengXY,OuYangRR,YuanMM,RenMY,GuFY,GuBW,CaoQ,SuXY,Guo-QiangChen,XiongSM,ZhangTD,WaxmanS,WangZY,ChenZ,HuJ,ShenZX,andChenSJ.StudiesontreatmentofAPLwitharsenictrioxide:remissioninduction,follow-upandmolecularmonitoringin11newlydiagnosedand47relapsedacutepromyelocyticleukemiapatients.Blood,1999;94:3315-3324
19.ZhuJ,GuoWM,YaoYY,ZhaoWL,PanL,CaiX,JuB,SunGL,WangHL,ChenSJ,Guo-QiangChen,CaenJ,ChenZ,WangZYTissuefactorsonacutepromyelocyticleukemiaandendothelialcellsaredifferentlyregulatedbyretinoicacid,arsenictrioxideandchemotherapeuticagents.Leukemia1999Jul;13(7):1062-70
20.Guo-QiangChen,Xue-GengShi,WeiTang,Shu-MinXiong,JunZhu,XunCai,Ze-GuangHan,Jian-HuaNi,Gui-YingShi,Pei-MingJia,Meng-MInLiu,Kai-LiHe,ChaoNiu,JunMa,PengZhang,Ting-DongZhang,PascalePaul,SamuelWaxman,Zhen-YiWang,Sai-JuanChen,ZhuChen.Useofarsenictrioxide(As2O3)inthetreatmentofacutepromyelocyticleukemia(APL):I.As2O3exertsdose-dependentdualeffectsonAPLCells.Blood1997,89:3345-3353.
21.Zhi-XiangShen,Guo-QiangChen,Jian-HuaNi,Xiu-ShongLi,Shu-MinXiong,Qian-YaoQiu,JunZhu,WeiTang,Kan-QiYang,YuChen,LiZhou,Zhi-WenFang,Yan-TingWang,JunMa,PengZhang,Ting-DongZhang,Sai-JuanChen,ZuChen,Zhen-YiWang.Useofarsenictrioxide(As2O3)inthetreatmentofacutepromyelocyticleukemia(APL):II.Clinicalefficacyandpharmacokineticsinrelapsedpatients.Blood1997,89:3354-3360
22.Guo-QiangChen,ZhixiangShen,FangWu,JieyinHan,JinmingMiao,HaojieZhong,XiusongLi,JingqiuZhao,JunZhu,ZhiwenFang,SaijuanChen,ZhuChen,ZhenyiWang.Pharmacokineticsandefficacyoflow-doseall-transretinoicacidinthetreatmentofacutepromyelocyticleukmia.Leukemia1996;10:825
23.Guo-QiangChen,JunZhu,Xue-GengShi,Jian-HuaNi,Hao-JieZhong,Gui-YingShi,Xiao-LongJin,WeiTang,Xiu-ShongLi,Shu-MingXong,Zhi-XiangShen,JunMa,PengZhang,Ting-DongZhang,ClaudeGazin,TomokiNaoe,Sai-JuanChen,Zhen-YiWang,ZhuChen.Invitrostudiesoncellularandmolecularmechanismsofarsenictrioxide(As2O3)inthetreatmentofAPL:As2O3inducesNB4cellapoptosiswithdown-regulationofBcl-2expressionandmodulationofPML-RARA/PMLProtein.Blood1996;88:1052
24.Su-YinZhang,JunZhu,Guo-QiangChen,Xin-XuDu,Li-JuanLu,ZhouZhang,Hao-JieZhong,Zhen-YiWang,RolandBerger,MichelLanotte,SamuelWaxman,ZhuChen,Sai-JuanChen.Establishmentofahumanacutepromyelocyticleukemia-ascitesmodelinSCIDmice.Blood1996;87:3404
25.陈国强、冉丕鑫主编.《基础病理生理学》.上海科学技术出版社
26.曾益新主编，陈国强等副主编.《肿瘤学》.人民卫生出版社